Cassava Sciences Gestione

Gestione criteri di controllo 3/4

Cassava Sciences Il CEO è Rick Barry, nominato in Sep2024, ha un mandato di meno di un anno. possiede direttamente 0.98% delle azioni della società, per un valore di € 1.92M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2 anni e 6.8 anni.

Informazioni chiave

Rick Barry

Amministratore delegato

US$546.2k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	1.0%
Durata media del management	2yrs
Durata media del Consiglio di amministrazione	6.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Rick Barry (65 yo)

less than a year

Mandato

US$546,155

Compensazione

Mr. Richard Jon Barry, also known as Rick, served as Independent Director at Cassava Sciences, Inc. since June 11, 2021, until July 17, 2024 and serves as its Executive Chairman of the Board since July 17,...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Richard Barry	CEO, President & Director	less than a year	US$546.16k	0.98% € 1.9m
Eric Schoen	Chief Financial Officer	6.1yrs	US$2.99m	0.048% € 95.5k
R. Cook	Senior VP	2.1yrs	US$1.27m	0% € 0
James Kupiec	Chief Medical Officer	3.8yrs	US$2.97m	0.0083% € 16.4k
George Thornton	Senior Vice President of Technology	no data	Nessun dato	Nessun dato
Michael Zamloot	Senior Vice President of Technical Operations	no data	Nessun dato	Nessun dato
Michael Marsman	Senior Vice President of Regulatory Affairs	2yrs	Nessun dato	Nessun dato
Lindsay Burns	Senior Vice President of Neuroscience	4.6yrs	Nessun dato	Nessun dato
Freda Nassif	Chief Commercial Officer	no data	Nessun dato	Nessun dato
Jaren Landen	Chief Clinical Development Officer	no data	Nessun dato	Nessun dato

2.0yrs

Durata media

62.5yo

Età media

Gestione esperta: Il team dirigenziale di PX91 è considerato esperto (durata media dell'incarico 2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Richard Barry	CEO, President & Director	3.4yrs	US$546.16k	0.98% € 1.9m
Patrick Scannon	Independent Director	16.9yrs	US$438.42k	0.0025% € 4.9k
Michael O'Donnell	Independent Director	26.4yrs	US$438.42k	0.017% € 33.8k
Grant Schoenhard	Member of Scientific Advisory Board	10.1yrs	US$558.31k	Nessun dato
Robert Gussin	Independent Director	21.7yrs	US$546.16k	0.026% € 52.2k
Claude Nicaise	Independent Chairman	less than a year	US$474.50k	0% € 0
Robert Anderson	Independent Director	less than a year	US$474.50k	0% € 0
Pierre Gravier	Independent Director	less than a year	US$474.50k	0% € 0

6.8yrs

Durata media

68.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PX91 sono considerati esperti (durata media dell'incarico 6.8 anni).

Cassava Sciences Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Cassava Sciences, Inc. Appoints Freda Nassif as Chief Commercial Officer

Cassava Sciences, Inc. Appoints Richard Barry as Chief Executive Officer

Cassava Sciences, Inc. Announces Demise of Sanford Robertson, Board Member

Cassava Sciences, Inc. Announces Chief Executive Officer Changes

Cassava Sciences, Inc., Annual General Meeting, May 09, 2024

Cassava Sciences, Inc. Announces Board Appointments

Recent updates

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

Cassava Sciences, Inc. Appoints Freda Nassif as Chief Commercial Officer

Cassava Sciences, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cassava Sciences, Inc. Appoints Richard Barry as Chief Executive Officer

New minor risk - Profitability

New major risk - Revenue and earnings growth

Cassava Sciences, Inc. Announces Demise of Sanford Robertson, Board Member

Cassava Sciences, Inc. Announces Expansion of Open-Label Extension Trials

Cassava Sciences, Inc. Announces Chief Executive Officer Changes

New minor risk - Profitability

New major risk - Revenue and earnings growth

New major risk - Share price stability

Cassava Sciences, Inc., Annual General Meeting, May 09, 2024

Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials

New major risk - Revenue and earnings growth

Cassava Sciences, Inc. Reports Results of Two-Year Clinical Safety Study of Simufilam, an Investigational Oral Drug for the Proposed Treatment of Alzheimer’s Disease Dementia

Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Growth-Dynamic Index

Cassava Sciences, Inc. Announces Board Appointments

New major risk - Revenue and earnings growth

Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’S Disease

Cassava Sciences, Inc. Announces Positive Safety Findings Based on Interim Magnetic Resonance Imaging Brain Data from Alzheimer's Patients

New major risk - Share price stability

Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease

Cassava Sciences, Inc. Announces Positive Interim Safety Review of Simufilam On-Going Phase 3 Trials in Patients with Alzheimer’s Disease

Independent Director recently bought €284k worth of stock

New major risk - Revenue and earnings growth

Cassava Sciences, Inc Announces Top-Line Clinical Results from Its Cognition Maintenance Study

Cassava Sciences, Inc. Announces the Publication of A New Paper in Frontiers in Aging

Independent Director recently bought €2.2m worth of stock

Forecast to breakeven in 2023

Cassava Sciences, Inc. Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease

Cassava Sciences, Inc. Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease

Cassava Sciences, Inc. Announces Executive Changes

Cassava Sciences, Inc. Announces Completion of Dosing in Open-Label Study of Simufilam for Alzheimer’s Disease

Cassava Sciences, Inc. Appoints Christopher Cook as Senior Vice President and General Counsel

Cassava Sciences Announces Initiation of an Open-Label Extension Study

Chief Clinical Development Officer recently bought €61k worth of stock

Lead Independent Director recently bought €2.0m worth of stock

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Cassava Sciences Announces Top-Line Results of 12-Month Interim Analysis from Open-Label Study Evaluating Simufilam in Alzheimer’s Disease

Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Filed Against Cassava Sciences, Inc

Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease

Insufficient new directors

No longer forecast to breakeven

No longer forecast to breakeven

Cassava Sciences, Inc.(NasdaqCM:SAVA) dropped from Russell Microcap Growth Index

Cassava Sciences, Inc. Provides Mid-Year Corporate Update, Clinical Development Progress and Announces Guidance on Clinical Data Release

Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer’S Disease

Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam

Cassava Sciences, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s Disease

Cassava Sciences’ Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim Analysis of Open-Label Study

New 90-day high: €10.77

Cassava Sciences, Inc. Appoints James Kupiec as Chief Clinical Development Officer

New 90-day low: €5.75

Cassava Sciences Announces Additional Clinical Data from a Phase 2b Study of Sumifilam in Alzheimer’S Disease

New 90-day high: €10.37

Independent Director recently bought €1.3m worth of stock

New 90-day high - €5.27

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media